SCHEMBL26857092

SCHEMBL26857092

Cc1cn(C)nc1CNC(=O)c1cc(-c2ccc3nc(N)nn3c2)cs1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ TTK P33981 3/20 0.40
▸ MARK3 P27448 5/20 0.39
▸ PIK3CG P48736 8/20 0.38
▸ PIK3CD O00329 7/20 0.38
▸ PIK3CA P42336 4/20 0.38
▸ PIK3CB P42338 3/20 0.38
▸ MAPK1 P28482 3/20 0.38
▸ MMP12 P39900 2/20 0.37
▸ SGK1 O00141 1/20 0.37
▸ CHEK1 O14757 1/20 0.37
▸ MAPK13 O15264 1/20 0.37
▸ PDPK1 O15530 1/20 0.37
▸ NUAK1 O60285 1/20 0.37
▸ CCNT1 O60563 1/20 0.37
▸ JAK2 O60674 1/20 0.37
▸ ROCK2 O75116 1/20 0.37
▸ CHEK2 O96017 1/20 0.37
▸ EGFR P00533 1/20 0.37
▸ RAF1 P04049 1/20 0.37
▸ NTRK1 P04629 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL26857089 0.86 MAPK1 (0.39) TTKMARK3PIK3CGPIK3CDPIK3CA
SCHEMBL26857023 0.85 PIK3CG (0.41) TTKPIK3CGPIK3CDPIK3CAPIK3CB
SCHEMBL26857094 0.84 MARK3 (0.44) TTKMARK3PIK3CGPIK3CDPIK3CA
SCHEMBL26857148 0.84 MARK3 (0.46) TTKMARK3PIK3CGPIK3CDPIK3CA
SCHEMBL26857084 0.84 PIK3CG (0.39) TTKPIK3CGPIK3CDPIK3CAPIK3CB
SCHEMBL26857046 0.84 TTK (0.41) TTKPIK3CGPIK3CDPIK3CAPIK3CB
SCHEMBL26857109 0.83 MARK3 (0.41) TTKMARK3PIK3CGPIK3CDPIK3CA
SCHEMBL26856882 0.83 MMP12 (0.53) TTKPIK3CGPIK3CDPIK3CBMAPK1
SCHEMBL26856951 0.83 ADORA2A (0.43) TTKPIK3CGPIK3CDMAPK1MMP12
SCHEMBL26857161 0.83 ADORA3 (0.42) TTKMARK3PIK3CGPIK3CDPIK3CA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230382904-A1 SUBSTITUTED 4-([1,2,4]TRIAZOLO[1,5-a]PYRIDIN-6-YL)THIOPHENE-2-CARBOXAMIDE DERIVATIVES AND USE THEREOF BAYER AKTIENGESELLSCHAFT (DE) 2023-11-30 — — US disclosed
US-20230382904-A1 SUBSTITUTED 4-([1,2,4]TRIAZOLO[1,5-a]PYRIDIN-6-YL)THIOPHENE-2-CARBOXAMIDE DERIVATIVES AND USE THEREOF BAYER AKTIENGESELLSCHAFT (DE) 2023-11-30 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230382904-A1 SUBSTITUTED 4-([1,2,4]TRIAZOLO[1,5-a]PYRIDIN-6-YL)THIOPHENE-2-CARBOXAMIDE DERIVATIVES AND USE THEREOF SNCA, PSEN2, PARK7 TTK 2266/4885MARK3 834/4885PIK3CG 690/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback